H1N1 Vaccine Deployment and Vaccination update
Outline

- Donor Commitments
- Vaccine Prequalification
- Country Preparedness
- Vaccine Deliveries
- Vaccine utilization and coverage
- Some lessons learned
Vaccine Deliveries, by Donor

- GSK, 31%
- USA, 21%
- France, 15%
- Sanofi Pasteur, 14%
- Australia, 5%
- UK, 4%
- Italy, 3%
- Switzerland, 2%
- CSL, 2%
- Belgium, 2%
- Norway, 1%
Donor Commitments: Finances

![Graph showing donor commitments over time, with highlighted pledges and commitments for each month from June 2009 to June 2010.]

- **USD, millions**: The vertical axis represents the amount of funds in millions of USD.
- **USD, millions**: The horizontal axis represents the months from June 2009 to June 2010.
- **Pledged** and **Committed**: Two bars indicate the pledged and committed amounts for each month, with committed amounts in darker shades.

### Key Points
- **June 2009**: Pledged $10 million, Committed $10 million.
- **July 2009**: Pledged $15 million, Committed $15 million.
- **August 2009**: Pledged $20 million, Committed $20 million.
- **September 2009**: Pledged $25 million, Committed $25 million.
- **October 2009**: Pledged $30 million, Committed $30 million.
- **November 2009**: Pledged $35 million, Committed $35 million.
- **December 2009**: Pledged $40 million, Committed $40 million.
- **January 2010**: Pledged $45 million, Committed $45 million.
- **February 2010**: Pledged $50 million, Committed $50 million.
- **March 2010**: Pledged $55 million, Committed $55 million.
- **April 2010**: Pledged $60 million, Committed $60 million.
- **May 2010**: Pledged $65 million, Committed $65 million.
- **June 2010**: Pledged $70 million, Committed $70 million.

**World Health Organization**

---

4 | H1N1 Pandemic Vaccine Deployment and Vaccination update
Donor Commitments: Vaccines

Note: Not all committed vaccine became immediately available for delivery
Vaccine Prequalification

Pandemic Influenza A (H1N1) vaccines prequalified by WHO

Cumulative number of vaccines

- Prequalification date
- Submission date

World Health Organization
Recipient Country Preparation: Summary

Number of countries fulfilling pre-supply requirements

- Letter of Intent
- Letter Agreement
- National Deployment Plan

07 Jan. 2010: First vaccine delivery
15 April 2010: Icelandic volcano disrupts shipment
### H1N1 Vaccine Utilization and Coverage by Region

<table>
<thead>
<tr>
<th>Region</th>
<th>Vaccine Utilization</th>
<th>Vaccine Coverage</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>by H1N1 target population*</td>
<td>by general population</td>
</tr>
<tr>
<td></td>
<td>Range</td>
<td>Average</td>
</tr>
<tr>
<td>AFRO</td>
<td>2-100%</td>
<td>61%</td>
</tr>
<tr>
<td>AMRO</td>
<td>10 -100%</td>
<td>64%</td>
</tr>
<tr>
<td>EMRO</td>
<td>0 – 82%</td>
<td>15%</td>
</tr>
<tr>
<td>EURO**</td>
<td>0.2% - 95%</td>
<td>57%</td>
</tr>
<tr>
<td>SEARO</td>
<td>25 - 77%</td>
<td>73%</td>
</tr>
<tr>
<td>WPRO</td>
<td>6-100%</td>
<td>53%</td>
</tr>
</tbody>
</table>

- Overall vaccination coverage in entire population in countries received vaccine from WHO: 6%
- Overall vaccination coverage in entire population at global level (exclude data from EUR countries under VENICE survey): 12 %
- Planned target population group as defined by country which is not necessary represent actual target population in the country
- ** Only data from 6 WHO eligible countries
% Vaccine Coverage by H1N1 target group population and entire population in African Region (n = 21)

Source: H1N1 Pandemic Vaccine Deployment and Vaccination survey and termination reports
%Vaccine Coverage by H1N1 target group population and entire population in American Region (n = 30)

Source: H1N1 Pandemic Vaccine Deployment and Vaccination survey and regional report
%Vaccine Coverage by H1N1 target group population and entire population in Eastern Mediterranean Region (n = 18)
Coverage is 0.0% for Pakistan, Somalia and Sudan

Mean: coverage by H1N1 target population = 6.2%
Mean: coverage by entire population = 0.6%
%Vaccine Utilization and Coverage by entire population in European Region (n = 6: only countries receiving vaccine from WHO)

Mean: Vaccine utilization = 57%
Mean: coverage by entire population = 4%

Utilization rate: countries received WHO donated vaccine
Vaccination coverage by entire population

Source: H1N1 Pandemic Vaccine Deployment and Vaccination survey and regional report
%Vaccine Coverage by H1N1 target group population and entire population in South East Asia Region (n = 7)

- Bangladesh
- DPRK
- Sri Lanka
- Timor Leste
- Maldives
- Bhutan
- Thailand

Mean: coverage by entire population = 6%

Source: H1N1 Pandemic Vaccine Deployment and Vaccination survey, and regional vaccination report
%Vaccine Coverage by H1N1 target group population and entire population in Western Pacific Region (n=26)

Mean: coverage by H1N1 target population = 64%
Mean: coverage by entire population = 8%

Source: WPRO H1N1 Pandemic Vaccine Deployment and Vaccination Monthly Update: February 2011, Country H1N1 vaccination termination reports
## % H1N1 Vaccination Uptake by H1N1 Target Group*

<table>
<thead>
<tr>
<th>Region</th>
<th>Health care workers</th>
<th>Pregnant women</th>
<th>Persons with underlying Conditions</th>
<th>Children</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Country</td>
<td>% Uptake*</td>
<td>Country</td>
<td>% Uptake*</td>
</tr>
<tr>
<td>AFRO</td>
<td>17/17</td>
<td>84%</td>
<td>17/17</td>
<td>48%</td>
</tr>
<tr>
<td>AMRO</td>
<td>23/23</td>
<td>100%</td>
<td>23/23</td>
<td>67%</td>
</tr>
<tr>
<td>EMRO</td>
<td>6/6</td>
<td>52%</td>
<td>4/6</td>
<td>7%</td>
</tr>
<tr>
<td>EURO**</td>
<td>6/6</td>
<td>62%</td>
<td>4/6</td>
<td>42%</td>
</tr>
<tr>
<td>SEARO</td>
<td>6/6</td>
<td>95%</td>
<td>6/6</td>
<td>86%</td>
</tr>
<tr>
<td>WPRO</td>
<td>9/9</td>
<td>86%</td>
<td>9/9</td>
<td>63%</td>
</tr>
</tbody>
</table>

* Uptake = doses administered in each target group per planned H1N1 target group population which may not be actual target population

**Data from countries receiving donated vaccine from WHO
Main Operational Lessons Learned

- Country plans must be tailored to specific contextual issues.
- Maintaining global and country communication channels is critical.
- Countries suggested more emphasis on social mobilization and communication.
- Global operational readiness and training needed as well as country readiness.
Main Operational Lessons Learned

- Legal framework of agreements should be maintained.
- A harmonized regulatory process across recipient countries could be useful.
- Cold chain capacity, global and country, may not be sufficient for future emergencies.
- Bundling of ancillary equipment remains crucial.

H1N1 vaccination – vaccine off load in Abuja, Nigeria
THANK YOU